Preparation of Papers for IFAC Conferences & Symposia: Adaptive fixture system for reducing machining distortion caused by residual stresses in milling

Autor: Landwehr, M., Kalocsay, R., Kolvenbach, C., Ganser, P., Bergs, T.

Publikováno v: In IFAC PapersOnLine 2022 55(2):264-269

Development of in silico models to predict viscosity and mouse clearance using a comprehensive analytical data set collected on 83 scaffold-consistent monoclonal antibodies.

Autor: Mock M; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Jacobitz AW; Process Development, Amgen Operations, Thousand Oaks, CA, USA., Langmead CJ; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Sudom A; Structural Biology, Amgen Research, South San Francisco, CA, USA., Yoo D; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Humphreys SC; Pharmacokinetics & Drug Metabolism, Amgen Research, South San Francisco, CA, USA., Alday M; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Alekseychyk L; Process Development, Amgen Operations, Thousand Oaks, CA, USA., Angell N; Process Development, Amgen Operations, Thousand Oaks, CA, USA., Bi V; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Catterall H; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Chen CC; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Chou HT; Structural Biology, Amgen Research, South San Francisco, CA, USA., Conner KP; Pharmacokinetics & Drug Metabolism, Amgen Research, South San Francisco, CA, USA., Cook KD; Pharmacokinetics & Drug Metabolism, Amgen Research, South San Francisco, CA, USA., Correia AR; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Dykstra A; Process Development, Amgen Operations, Thousand Oaks, CA, USA., Ghimire-Rijal S; Structural Biology, Amgen Research, Thousand Oaks, CA, USA., Graham K; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Grandsard P; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Huh J; Process Development, Amgen Operations, Thousand Oaks, CA, USA., Hui JO; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Jain M; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Jann V; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Jia L; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Johnstone S; Structural Biology, Amgen Research, South San Francisco, CA, USA., Khanal N; Process Development, Amgen Operations, Thousand Oaks, CA, USA., Kolvenbach C; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Narhi L; Process Development, Amgen Operations, Thousand Oaks, CA, USA., Padaki R; Process Development, Amgen Operations, Thousand Oaks, CA, USA., Pelegri-O'Day EM; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Qi W; Process Development, Amgen Operations, Thousand Oaks, CA, USA., Razinkov V; Process Development, Amgen Operations, Thousand Oaks, CA, USA., Rice AJ; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Smith R; Pharmacokinetics & Drug Metabolism, Amgen Research, South San Francisco, CA, USA., Spahr C; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Stevens J; Process Development, Amgen Operations, Thousand Oaks, CA, USA., Sun Y; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Thomas VA; Pharmacokinetics & Drug Metabolism, Amgen Research, South San Francisco, CA, USA., van Driesche S; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Vernon R; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Wagner V; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Walker KW; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Wei Y; Process Development, Amgen Operations, Thousand Oaks, CA, USA., Winters D; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Yang M; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA., Campuzano IDG; Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA.

Publikováno v: MAbs [MAbs] 2023 Jan-Dec; Vol. 15 (1), pp. 2256745.

Stability of Protein Pharmaceuticals: Recent Advances.

Autor: Manning MC; Legacy BioDesign LLC, Johnstown, CO, USA. manning@legacybiodesign.com.; Department of Chemistry, Colorado State University, Fort Collins, CO, USA. manning@legacybiodesign.com., Holcomb RE; Legacy BioDesign LLC, Johnstown, CO, USA.; Department of Chemistry, Colorado State University, Fort Collins, CO, USA., Payne RW; Legacy BioDesign LLC, Johnstown, CO, USA.; Department of Chemistry, Colorado State University, Fort Collins, CO, USA., Stillahn JM; Legacy BioDesign LLC, Johnstown, CO, USA.; Department of Chemistry, Colorado State University, Fort Collins, CO, USA., Connolly BD; Spyre Therapeutics, Inc., Waltham, MA, USA., Katayama DS; Samsung Biologics, 201-2, Songdo-Dong, Yeonsu-Gu, Incheon, Korea., Liu H; Scholar Rock, Inc., Cambridge, MA, USA., Matsuura JE; Jim Matsuura Pharma Consulting LLC, Lafayette, CO, USA., Murphy BM; Just-Evotec, Seattle, WA, USA., Henry CS; Department of Chemistry, Colorado State University, Fort Collins, CO, USA., Crommelin DJA; Utrecht University, Utrecht, Netherlands.

Publikováno v: Pharmaceutical research [Pharm Res] 2024 Jul; Vol. 41 (7), pp. 1301-1367. Date of Electronic Publication: 2024 Jun 27.

Prediction of the Hydrogen Peroxide-Induced Methionine Oxidation Propensity in Monoclonal Antibodies.

Autor: Agrawal NJ; Amgen Inc., Process Development, Cambridge, Massachusetts 02141., Dykstra A; Amgen Inc., Process Development, Thousand Oaks, California 91320., Yang J; Amgen Inc., Process Development, Thousand Oaks, California 91320., Yue H; Amgen Inc., Process Development, Thousand Oaks, California 91320., Nguyen X; Amgen Inc., Process Development, Thousand Oaks, California 91320., Kolvenbach C; Amgen Inc., Process Development, Thousand Oaks, California 91320., Angell N; Amgen Inc., Process Development, Thousand Oaks, California 91320.

Publikováno v: Journal of pharmaceutical sciences [J Pharm Sci] 2018 May; Vol. 107 (5), pp. 1282-1289. Date of Electronic Publication: 2018 Jan 08.

Heterogeneity in Disulfide Bond Reduction in IgG1 Antibodies Is Governed by Solvent Accessibility of the Cysteines.

Autor: Natesan, Ramakrishnan¹ (AUTHOR) rnatesan@amgen.com, Dykstra, Andrew B.² (AUTHOR) adykstra@amgen.com, Banerjee, Akash¹ (AUTHOR) abaner12@amgen.com, Agrawal, Neeraj J.¹ (AUTHOR) agrawaln@amgen.com

Publikováno v: Antibodies (2073-4468). Dec2023, Vol. 12 Issue 4, p83. 17p.